|
|
|
| Comparison of clinical effect of different doses of pulmonary surfactant combined with nasal non-invasive high-frequency ventilation for treating preterm infants with respiratory distress syndrome |
| The Third Affiliated Hospital of Chengdu Medical College, Pidu District People's Hospital of Chengdu, Chengdu, Sichuan Province, 611730 |
|
|
|
|
Abstract To explore the clinical effect of different doses of pulmonary surfactant combined with nasal non-invasive high-frequency ventilation for treating preterm infants with respiratory distress syndrome (RDS). Methods: The data of 121 preterm infants with RDS from January 2019 to January 2022 were collected. According to the different drug doses, these infants were divided into two groups. 62 infants in the study group were given treatment of high-dose pulmonary surfactant (100 mg/kg) combined with nasal non-invasive high-frequency ventilation and 59 infants in the control group were given treatment of low-dose pulmonary surfactant (70 mg/kg) combined with nasal non-invasive high-frequency ventilation. The hospitalization time, the time of respirator used, the clinical efficacy, the values of blood gas analysis indexes, and the pulmonary oxygenation function indexes, such as ratio of arterial oxygen partial pressure to alveolar oxygen partial pressure (a/APO2) and oxygenation index (OI), and the complications rate of the infants were compared between the two groups. Results: The duration of hospital stay (10.3±2.3d) and the time of respirator used (81.7±14.3h) of the infants in the study group were significantly lower than those (13.9±2.2d and 125.2±17.9h) of the infants in the control group. The total effective rate (95.2%) of the infants in the study group was significantly higher than that (81.4%) of the infants in the control group (all P＜0.05). There was no significant difference in the pH value of the infants between the two groups (P＞0.05). The changes of a/APO2 and OI levels of the infants in the study group were significantly better than those of the infants in the control group (P＞0.05). There was no significant difference in the complication rate (8.1% vs. 13.6%) of the infants between the two groups (P＞0.05). Conclusion: 100 mg/kg pulmonary surfactant combined with nasal noninvasive high-frequency ventilation for treating preterm infants with RDS can increase the clinical effect and can improve the blood gas-related indexes and pulmonary oxygenation function of the infants betterly, with higher safety.
|
|
|
|
|
|
|
|
|
